Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Y90 Radiation Segmentectomy vs SBRT for HCC (SBRT vs Y90)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04235660
Recruitment Status : Recruiting
First Posted : January 22, 2020
Last Update Posted : August 30, 2021
Sponsor:
Information provided by (Responsible Party):
Paul Michael Haste, MD, Indiana University

Brief Summary:
The proposed study is a single site, prospective, randomized pilot study to assess the feasibility of recruitment of patients into a trial evaluating the efficacy and tolerability of selective transarterial Y90 radioembolization (radiation segmentectomy) versus stereotactic body radiation therapy (SBRT) for solitary early stage (≤ 3cm) hepatocellular carcinoma (HCC).

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma (HCC) Radiation: Yttrium-90 Radiation Segmentectomy Radiation: Stereotactic Body Radiation Therapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Masking Description: Radiologist assessing response will be blinded to the treatment type
Primary Purpose: Treatment
Official Title: Yttrium-90 Radiation Segmentectomy Versus Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Early Stage Hepatocellular Carcinoma (HCC): A Pilot Study
Actual Study Start Date : July 22, 2020
Estimated Primary Completion Date : May 2024
Estimated Study Completion Date : May 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Yttrium

Arm Intervention/treatment
Active Comparator: Yttrium-90 Radiation Segmentectomy Radiation: Yttrium-90 Radiation Segmentectomy
This therapy arm involves two separate steps, a planning/mapping arteriogram and a therapy delivery. The planning arteriogram will be performed to confirm arterial anatomy is acceptable for RS (≤2 segment delivery) and that lung shunting is not too high to preclude treatment with RS. Once confirmed, patients will return for RS (within 45 days of mapping). Dose will be calculated based off the desired treatment volume using pre-treatment cross-sectional imaging. The desired segmental dose will be calculated to be ≥ 200Gy. RS will be performed by one of three separate interventional radiologists with experience in radioembolization. Actual administered activity and location of dose administration will be recorded.

Active Comparator: Stereotactic Body Radiation Therapy Radiation: Stereotactic Body Radiation Therapy
SBRT will be delivered with linear accelerator-based photon beams with either fixed angle non- coplanar fields or dynamic arcs. An internal target volume (ITV) will be generated to account for tumor movement during breathing cycle. Finally, a planning target volume (PTV) will be an expansion of 3- 5mm from the ITV. For Child Pugh A patients, prescription dose will either be 5000cGy in 5 fractions delivered every other day or 4800cGy in 3 fractions delivered twice weekly. For Child Pugh B patients, prescription dose of 4000cGy in 5 fractions delivered every other day. Inverse planning will be used. 95% of the PTV or more will receive at least 100% of the prescription dose. Normal tissue dose constraints for each dose level will be respected with acceptable deviations permitted as outlined in appendix VII. Patients will be seen at least once per week by a clinician to grade toxicities, with on- treatment labs (CBC, CMP, INR) each week.




Primary Outcome Measures :
  1. Feasibility of Recruitment (Recruitment Rate) [ Time Frame: 24 months ]
    Feasibility of recruitment will be measured by evaluating the proportion of patients enrolled versus those approached for the study after they have been determined to be a candidate.


Secondary Outcome Measures :
  1. Proportion of patients with any toxicities [ Time Frame: 24 months ]
    the proportion of patients with any toxicities (≥ grade 4) using CTCAE between RS and SBRT for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC).

  2. Mean change in hepatobiliary function [ Time Frame: 24 months ]
    the mean change in hepatobiliary function, as measured 3 months after treatment using a functional HIDA scan, between RS and SBRT for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC).

  3. Mean change in Functional Assessment of Cancer Therapy- General (FACT-G) score [ Time Frame: 6 months ]
    the mean change in patient-reported outcomes from baseline, at 1, 3 and 6 months, between RS and SBRT, for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC), using the Functional Assessment of Cancer Therapy- General (FACT-G) and

  4. Mean change in Comprehensive Score for Financial Toxicity [ Time Frame: 6 months ]
    the mean change in patient-reported outcomes from baseline, at 1, 3 and 6 months, between RS and SBRT, for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC), using the Comprehensive Score for Financial Toxicity (COST)

  5. Disease-free survival (DFS) rates of RS and SBRT [ Time Frame: 24 months ]
    the disease-free survival (DFS) rates of RS and SBRT at 2 years using mRECIST on CT or MR for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC).

  6. Time-to-secondary treatment (TTST) between RS and SBRT [ Time Frame: 24 months ]
    time-to-secondary treatment (TTST) between RS and SBRT for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC) up to 2 years after initial treatment.

  7. Objective response rate [ Time Frame: 6 months ]
    the objective response rate (ORR) of radiation segmentectomy (RS) and stereotactic body radiation therapy (SBRT) as measured at 6 months using mRECIST (appendix IV) for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC) to better allow for an appropriately powered trial evaluating the efficacy of these treatments.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to provide written informed consent and HIPAA authorization
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥ 18 years at time of informed consent
  • Solitary HCC (≤3 cm) diagnosed by imaging (LI-RADS 4-5) or histology
  • Childs-Pugh score ≤ 7
  • ECOG performance status 0-1
  • Tumor location/characteristics eligible for either SBRT or Y90 therapy as deemed by local tumor board
  • Adequate organ function defined as:

    1. serum bilirubin < 4.0 mg/dL ,
    2. albumin > 2 g/dL

Exclusion Criteria:

  • Any prior locoregional therapy to the target tumor
  • Any prior radiation therapy to the liver
  • Pregnancy or lactation: Women of childbearing potential must have a negative pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:

    i. Has undergone a hysterectomy or bilateral oophorectomy; or ii. Has been naturally amenorrheic for at least 24 consecutive months

  • Known severe allergic reaction (anaphylaxis) to iodinated contrast
  • Coagulopathy (platelets < 50 K/mm3 and/or INR > 2) not correctable by transfusion
  • Macrovascular invasion or extrahepatic HCC

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04235660


Contacts
Layout table for location contacts
Contact: Paul Haste, MD 317-944-5005 phaste@iupui.edu

Locations
Layout table for location information
United States, Indiana
Indiana University Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Hayley Trussell, RN-BSN    317-963-0305    hktrusse@iu.edu   
Principal Investigator: Paul Haste, MD         
Sponsors and Collaborators
Indiana University
Layout table for additonal information
Responsible Party: Paul Michael Haste, MD, Assistant Professor of Clinical Radiology & Imaging Sciences, Indiana University
ClinicalTrials.gov Identifier: NCT04235660    
Other Study ID Numbers: IU-2001712954
First Posted: January 22, 2020    Key Record Dates
Last Update Posted: August 30, 2021
Last Verified: August 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases